Answers are grounded in this paper and cite their sources.
This study provides Class IV evidence that rituximab decreases the annualized relapse rate in AQP4-IgG-seropositive NMOSD and MOGAD.
No takes yet. Share an insight, caveat, or question.
Barreras et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: